Sign in

SGMT on Nasdaq

Sagimet Biosciences Inc.

In its 2026 annual report the company says: “We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer.”5 It is headquartered in San Mateo, United States.2 Its shares trade on Nasdaq under the symbol SGMT.2

Price unavailable

Last updated Oct 21, 2026.

Overview

-$51.0MNet income, fiscal 20253

Compare with Oramed Pharmaceuticals, Cocrystal Pharma, Inc. or Lipocine Inc., or pick any stock.

  • TickerSGMT on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersSan Mateo, United States2
  • Incorporated inDE4
  • Business address950 Tower Lane, Ste 1500, Foster City, Ca 944044
  • Filer category, Emerging growth company4
  • Legal formCorporation2
  • LEI2549002OT2F8BV0VPD022
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o Paracorp Incorporated, 19934 Camden, United States2
  • Registered withDivision of Corporations, Department of State, 42727842

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Our second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-1537.0%Operating margin6
-1393.8%Net margin6
-30.6%Return on equity3

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$19.8M

Out of $2.0M in revenue.6 The company lost money this year.

Financial statements

Operating income76-$30.7M in 2023−1% since 2022
-$40.0M-$30.0M-$20.0M-$10.0M02022: -$31.1M-$31.1M20222023: -$30.7M-$30.7M2023−1%
Net income76-$27.9M in 2023−9% since 2022
-$40.0M-$30.0M-$20.0M-$10.0M02022: -$30.5M-$30.5M20222023: -$27.9M-$27.9M2023−9%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Research and development expenses$39.1M$38.4M
General and administrative expenses$17.8M$16.0M
Total operating expenses$56.9M$54.5M
Loss from operations-$56.9M-$54.5M
Interest income and other, net$5.9M$8.9M
Total other income$5.9M$8.9M
Net loss-$51.0M-$45.6M
Net loss per share, basic (in dollars per share)-$1.58-$1.45
Net loss per share, diluted (in dollars per share)-$1.58-$1.45
Weighted-average shares outstanding, basic (in shares)32.3M shares31.4M shares
Weighted-average shares outstanding, diluted (in shares)32.3M shares31.4M shares
Net unrealized gain (loss) on marketable securities-$110.0K$200.0K
Total comprehensive loss-$51.1M-$45.4M

Compare Sagimet Biosciences Inc. with another company

Corporate structure

Sagimet Biosciences Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Sagimet Biosciences Inc.

  • Commodore Capital LP Filed SCHEDULE 13G on Sagimet Biosciences Inc., latest Oct 7, 2026
  • BALYASNY ASSET MANAGEMENT L.P. Filed SCHEDULE 13G on Sagimet Biosciences Inc., latest Aug 14, 2026
  • BlackRock Filed SCHEDULE 13G on Sagimet Biosciences Inc., latest Jul 30, 2026
  • KPCB PANDEMIC & BIO DEFENSE FUND LLC Filed SCHEDULE 13G/A on Sagimet Biosciences Inc., latest Dec 18, 2025 (2 filings since Feb 14, 2024)
  • Woodline Partners LP Filed SCHEDULE 13G/A on Sagimet Biosciences Inc., latest Nov 14, 2025 (2 filings since Aug 14, 2025)
  • Point72 Asset Management, L.P. Filed SCHEDULE 13G/A on Sagimet Biosciences Inc., latest Aug 14, 2025 (4 filings since Feb 5, 2024)
  • AP11 Ltd Filed SCHEDULE 13G/A on Sagimet Biosciences Inc., latest Jun 24, 2025 (2 filings since May 20, 2025)
  • NEW ENTERPRISE ASSOCIATES 13 LP Filed SCHEDULE 13G/A on Sagimet Biosciences Inc., latest May 13, 2025 (2 filings since Feb 14, 2024)
  • Blue Owl Capital Filed SCHEDULE 13G/A on Sagimet Biosciences Inc., latest Feb 14, 2025 (2 filings since Nov 14, 2024)
  • BAKER BROS. ADVISORS LP Filed SC 13G/A on Sagimet Biosciences Inc., latest Nov 14, 2024 (2 filings since Feb 14, 2024)
  • HILLHOUSE INVESTMENT MANAGEMENT, LTD. Filed SC 13G/A on Sagimet Biosciences Inc., latest Nov 14, 2024 (2 filings since Feb 14, 2024)
  • FMR LLC Filed SC 13G/A on Sagimet Biosciences Inc., latest Mar 11, 2024 (3 filings since Sep 11, 2023)
  • Sagimet Biosciences Inc. San Mateo, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Sagimet Biosciences Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$78.0K3 Dec 31, 2025$77.0K3 Dec 31, 2024+1.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$35.0M3 Dec 31, 2025$75.8M3 Dec 31, 2024−53.8%
Marketable securities, current$78.1M3 Dec 31, 2025$75.4M3 Dec 31, 2024+3.6%
Marketable securities, non-current$03 Dec 31, 2025$7.4M3 Dec 31, 2024−100.0%

Properties, in its own words

Our headquarters is currently located in San Mateo, California and consists of approximately 3,000 square feet of office space under a lease that expires in June 2026. We believe that our facilities are adequate to meet our current needs. We plan to reassess our facilities needs on a quarterly basis.

Item 2 of the 10-K filed Mar 11, 2026.5

Leadership

Who has led Sagimet Biosciences Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David Happel2023–now

Chair

  1. George Kemble2023–now

President

  1. David Happel2023–now

Chief financial officer

  1. Dennis Hom2023
  2. Thierry Chauche2024–now

Chief operating officer

  1. Anthony M. Rimac2023
2025
Board members and other officers (16)

Former names

  • 3-V Biosciences, Inc.May 8, 2007 to Feb 25, 20194

Timeline

  1. Oct 1, 20268-K Entered a material agreement32
  2. Sep 30, 20268-K Regulation FD disclosure; Other events33
  3. Aug 13, 20268-K Other events34
  4. Aug 11, 20268-K Results of operations; Regulation FD disclosure35
  5. Jul 21, 20268-K Regulation FD disclosure36
  6. Jun 12, 20268-K Executive or director change; Shareholder vote37
  7. Jun 3, 20268-K Executive or director change38
  8. May 12, 20268-K Results of operations39
  9. Apr 28, 20268-K Entered a material agreement40
  10. Apr 27, 20268-K Results of operations; Regulation FD disclosure; Other events41
  11. Apr 27, 20268-K Regulation FD disclosure42
  12. Apr 21, 20268-K Executive or director change; Other events43
  13. Jul 13, 2023New chief executive David Happel becomes CEO12

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.40) a share, on Nov 13, 2025.44

When it reported results

  1. Aug 11, 2026Reported quarterly or annual results35
  2. May 12, 2026Reported quarterly or annual results39
  3. Apr 27, 2026Reported quarterly or annual results41
  4. Mar 11, 2026Reported quarterly or annual results45
  5. Nov 13, 2025Reported quarterly or annual results46
  6. Aug 13, 2025Reported quarterly or annual results47
  7. May 8, 2025Reported quarterly or annual results48
  8. Mar 12, 2025Reported quarterly or annual results49

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

249 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 53 major events, 100 insider forms, 24 large holders, 59 other. The latest 20:

  1. Oct 7, 2026SCHEDULE 13G EDGAR
  2. Oct 1, 20268-K EDGAR
  3. Oct 1, 2026424B5 EDGAR
  4. Sep 30, 20268-K EDGAR
  5. Sep 30, 2026424B3 EDGAR
  6. Aug 17, 20264 EDGAR
  7. Aug 14, 2026144 EDGAR
  8. Aug 14, 2026SCHEDULE 13G EDGAR
  9. Aug 13, 20268-K EDGAR
  10. Aug 12, 20264 EDGAR
  11. Aug 11, 2026144 EDGAR
  12. Aug 11, 20268-K EDGAR
  13. Aug 11, 202610-Q EDGAR
  14. Jul 30, 2026SCHEDULE 13G EDGAR
  15. Jul 22, 20264 EDGAR
  16. Jul 22, 20264 EDGAR
  17. Jul 22, 20264 EDGAR
  18. Jul 21, 20268-K EDGAR
  19. Jul 20, 2026144 EDGAR
  20. Jun 15, 20264 OWNERSHIP DOCUMENT EDGAR

The 249 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 5 buys and 18 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 14, 2026Kemble GeorgeDirectorSale350,987$10.23$3.6MForm 4
Aug 11, 2026Kemble GeorgeDirectorSale20,206$9.95$201.1KForm 4
Jul 20, 2026Happel DavidPresident & CEOSale64,051$7.76$497.0KForm 4
Jul 20, 2026Rozek ElizabethChief Legal & Admin. OfficerSale10,545$7.76$81.8KForm 4
Jul 20, 2026Kemble GeorgeDirectorSale18,844$7.46$140.6KForm 4
Feb 10, 2026Happel DavidPresident & CEOSale12,101$5.36$64.9KForm 4
Feb 10, 2026Chauche ThierryChief Financial OfficerSale1,312$5.36$7.0KForm 4
Feb 10, 2026Martins Eduardo BrunoChief Medical OfficerSale3,640$5.36$19.5KForm 4
Feb 10, 2026Rozek ElizabethChief Legal & Admin. OfficerSale2,622$5.36$14.1KForm 4
Nov 20, 2025Kemble GeorgeDirectorSale37,688$7.69$289.8KForm 4
Jul 21, 2025Happel DavidPresident & CEOSale65,478$9.13$597.8KForm 4
Jul 21, 2025Martins Eduardo BrunoChief Medical OfficerSale8,277$9.13$75.6KForm 4
Jul 21, 2025Rozek ElizabethChief Legal & Admin. OfficerSale10,780$9.13$98.4KForm 4
Jul 23, 2024Kemble GeorgeDirectorSale23,625$3.17$74.9KForm 4
Jul 19, 2024Martins Eduardo BrunoChief Medical OfficerSale8,357$3.10$25.9KForm 4
Jul 19, 2024Rozek ElizabethChief Legal & Admin. OfficerSale10,914$3.10$33.8KForm 4
Jul 19, 2024Kemble GeorgeDirectorSale14,062$3.10$43.6KForm 4
Mar 26, 2024Happel DavidPresident & CEOBuy12,100$5.27$63.8KForm 4
Dec 7, 2023Happel DavidPresident & CEOBuy1,600$4.10$6.6KForm 4
Nov 16, 2023Happel DavidPresident & CEOBuy590$2.35$1.4KForm 4

All 23 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025David HappelPresident and Chief Executive Officer64$630.0K$3.2M62
2025Elizabeth Rozek, Esq.Chief Legal and Administrative Officer54$483.3K$1.5M62
2025Eduardo Bruno Martins, M.D., D.Phil.Former Chief Medical Officer 63$500.0K$1.4M62
2024David HappelPresident and Chief Executive Officer64$582.0K$906.2K62
2024Eduardo Bruno Martins, M.D., D.Phil.Former Chief Medical Officer 63$475.0K$669.1K62
2024Elizabeth Rozek, Esq.Chief Legal and Administrative Officer54$446.0K$626.1K62

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.6,575,788$50.8M0.0%+5,775,845
Balyasny Asset Management L.P.3,626,113$28.0M0.1%New
Woodline Partners LP3,000,652$23.2M0.1%+1,999,709
Silverarc Capital Management, LLC2,927,698$22.6M2.5%New
Vanguard Capital Management LLC2,566,272$19.8M0.0%+1,467,353
Bvf Inc/il2,500,000$19.3M0.5%New
Caligan Partners LP2,500,000$19.3M0.9%New
Affinity Asset Advisors, LLC2,497,864$19.3M1.0%+1,629,844
Federated Hermes, Inc.2,086,715$16.1M0.0%+2,085,934
Great Point Partners LLC2,029,933$15.7M3.7%New
State Street Corp1,995,092$15.4M0.0%+1,866,304
Saturn V Capital Management LP1,479,918$11.4M1.6%New
Geode Capital Management, LLC1,444,019$11.2M0.0%+1,134,497
Blue Owl Capital Holdings LP1,260,544$9.7M1.5%+926,667
Baker Bros. Advisors LP952,996$7.4M0.0%No change
Millennium Management LLC937,025$7.2M0.0%+74,722
Aberdeen Group plc847,700$6.6M0.0%New
Goldman Sachs Group Inc759,086$5.9M0.0%+589,827
Hhlr Advisors, Ltd.724,800$5.6M0.7%No change
Ameriprise Financial Inc581,217$4.5M0.0%New
Vestal Point Capital, LP535,452$4.1M0.1%New
Northern Trust Corp468,385$3.6M0.0%+412,874
Boothbay Fund Management, LLC464,095$3.6M0.1%New
ADAR1 Capital Management, LLC437,500$3.4M0.2%New
Farallon Capital Management, L.l.c.415,000$3.2M0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Sagimet Biosciences Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSagimet Biosciences Inc.1
  • CIK0001400118
  • Employer ID (EIN)20-59914725
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address950 Tower Lane, Ste 1500, Foster City, CA 944041
  • Phone(650) 561-86001
  • Shares outstanding32,017,613 Common Class A shares; 567,494 Common Class B shares as of Mar 5, 20265
  • Public float$228.4M as of Jun 30, 20255
  • AuditorKPMG LLP, Philadelphia, Pennsylvania PCAOB ID 185; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceMay 8, 20071
  • Filings261 in all: 4 (80), 8-K (52), 3 (20), 10-Q (10), CORRESP (7), D (7), SC 13G (7), SCHEDULE 13G/A (7)1
    All 35 form types

    S-8 (6), UPLOAD (6), 144 (5), SC 13G/A (5), SCHEDULE 13G (5), S-1/A (4), 10-K (3), 424B5 (3), ARS (3), DEF 14A (3), DRS (3), EFFECT (3), S-1 (3), SEC STAFF LETTER (3), 424B4 (2), DRS/A (2), DRSLTR (2), 424B3 (1), 8-A12B (1), 8-K/A (1), CERT (1), D/A (1), DEFA14A (1), REGDEX (1), RW (1), S-1MEF (1), S-3 (1)

  • Latest filingsAnnual report (10-K) Mar 11, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) Apr 21, 2026
    Latest 8-K (8-K) Oct 1, 2026

Securities registered for trading

ClassSymbolExchange
Series A Common Stock,$0.0001 par value per shareSGMTNasdaq Global Market

From the cover page of the 10-K filed Mar 11, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Sagimet Biosciences Inc. names in Item 1A of its 10-K filed Mar 11, 2026: 74 risks under these headings, as written.5

  • Risks related to our business
  • We have incurred significant operating losses since our inception, and we expect to incur significant operating losses for the foreseeable future. We may never become profitable or, if profitability is achieved, be able to sustain profitability.
  • We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.
  • Currently our business depends on the success of our lead drug candidate, denifanstat, which is still in clinical development. If we are unable to obtain regulatory approval for or successfully commercialize denifanstat, our business will be materially harmed.
  • If we encounter difficulties enrolling patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. If clinical trials or regulatory approval processes for our drug candidates are prolonged, delayed or suspended, we may be unable to seek regulatory approval for and commercialize our drug candidates on a timely basis, which would require us to incur additional costs and substantially harm our business.
  • We may not be successful in our efforts to expand our pipeline, including by identifying additional indications for which to investigate denifanstat or TVB-3567 in the future. We may expend our limited resources to pursue a particular indication or formulation for denifanstat or TVB-3567, or a combination with denifanstat or TVB-3567 and another molecule, and fail to capitalize on other drug candidates, indications or formulations that may be more profitable or for which there is a greater likelihood of success.
  • We have conducted, are currently conducting, and may in the future conduct clinical trials for our drug candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
  • Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • We intend to develop certain of our drug candidates in combination with other approved and investigational therapies, which exposes us to additional risks.
  • If we or third parties are unable to successfully develop technologies or establish tests for biomarkers that enable patient selection or monitoring for drug responses, or if we experience significant delays in doing so, we may not realize the full commercial potential of our drug candidates.
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed.
The other 63 risks
  • Obtaining and maintaining regulatory approval for a drug candidate in one jurisdiction does not mean that we will be successful in obtaining regulatory approval for that drug candidate in other jurisdictions.
  • We may not be able to file INDs or IND amendments, or comparable foreign applications, to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA or comparable foreign regulatory authorities may not permit us to proceed.
  • Use of denifanstat, TVB-3567 or any future drug candidates, or the use of our drug candidates in combination with other molecules, could be associated with side effects, adverse events or other properties that could delay or prevent regulatory approval or result in significant negative consequences following marketing approval, if any.
  • Although we have received Breakthrough Therapy designation for denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), this may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood of receiving marketing approval in the United States.
  • We have received Fast Track designation for denifanstat for F2-F3 MASH and may seek such designation for our other drug candidates or for other indications, but we might not receive such designations, and even if we do, such designations may not actually lead to a faster development or regulatory review or approval process.
  • Our drug candidates will remain subject to ongoing regulatory review even if they receive marketing approval, and if we fail to comply with continuing regulations, we could lose these approvals and the sale of any approved commercial products could be suspended.
  • Changes in the manufacturing process or formulation may result in additional costs or delay.
  • Changes in funding for the FDA and other domestic and foreign government authorities could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.
  • Our industry is highly competitive, and our drug candidates may become obsolete.
  • Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize denifanstat and any future drug candidates and may affect the prices we may set.
  • If any product liability lawsuits are brought against us or any of our collaborative partners, we may incur substantial liabilities and may be required to limit commercialization of our drug candidates.
  • Our employees, contractors and partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.
  • If we fail to develop and commercialize other drug candidates, we may be unable to grow our business.
  • If we are unable to successfully validate, develop and obtain regulatory approval for diagnostic tests for certain of our drug candidates that would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these drug candidates.
  • We may engage in strategic transactions that could increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, subject us to other risks, adversely affect our liquidity, increase our expenses and present significant distractions to our management.
  • Any pandemic, epidemic, or outbreak of an infectious disease may materially and adversely affect our business and our financial results and could cause a disruption to the development of our drug candidates.
  • Risks related to intellectual property
  • If we are unable to obtain, maintain and enforce sufficient patent protection for our drug candidates, or if the scope of the patent protection is not sufficiently broad, third parties, including our competitors, could develop and commercialize products similar or identical to ours, and our ability to commercialize our drug candidates successfully may be adversely affected.
  • Our pending patent applications may not result in issued patents if other parties invented or filed patent applications on the same technology prior to our invention or filing of patent applications on our technology.
  • We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue, or that our issued patents or patents that issue in the future will not be challenged and rendered invalid and/or unenforceable.
  • Our pending and future patent applications may not result in patents being issued that protect our drug candidates, in whole or in part, or which effectively prevent others from commercializing competitive products.
  • Our patents may be subject to a reservation of rights by one or more third parties.
  • Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We may become involved in lawsuits or administrative disputes to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
  • We may not be able to enforce our intellectual property rights throughout the world.
  • We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.
  • If we are sued for infringing, misappropriating or otherwise violating intellectual property rights of third parties, such litigation or disputes could be costly and time consuming and could prevent or delay us from developing or commercializing our drug candidates.
  • We may be subject to claims by third parties asserting that our employees or consultants or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property, or we may need to bring similar claims against third parties.
  • We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • The term of our patents may be inadequate to protect our competitive position on our products.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent offices, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If we are unable to protect the confidentiality of our trade secrets and proprietary know-how, the value of our technology could be materially adversely affected, and our business would be harmed.
  • If we fail to comply with our obligations under any license, collaboration or other agreement, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our drug candidates.
  • Intellectual property rights do not necessarily address all potential threats.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • Risks related to third parties
  • We have licensed rights to denifanstat to Ascletis for Greater China. Under the license agreement, Ascletis controls certain product development efforts in its territory, including conduct of clinical trials, which could have an impact on our clinical development programs.
  • We rely on third parties to conduct our clinical trials of our drug candidates and expect to rely on third parties to conduct future clinical trials, as well as investigator-sponsored clinical trials of our drug candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.
  • Disputes under key agreements or conflicts of interest with our scientific advisors or clinical investigators could delay or prevent development or commercialization of our drug candidates.
  • We currently have no marketing and sales organization and have no organizational experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell denifanstat, TVB-3567 and any future drug candidates, we may not be able to generate product revenues.
  • Risks related to our industry and the regulatory environment in which we operate
  • A drug candidate may not achieve adequate market acceptance among physicians, patients, third-party payors and others in the medical community necessary for commercial success.
  • Our ability to commercialize any products successfully will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations.
  • Our relationships with customers, healthcare providers, and third-party payors may be subject, directly or indirectly, to federal, state and foreign healthcare fraud and abuse laws, transparency laws, and other healthcare laws and regulations, including analogous foreign laws. If we or our employees, independent contractors, consultants, commercial partners, or vendors violate these laws, we could face substantial penalties.
  • Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer cybersecurity incidents or breaches and we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, loss of customers or sales, and other adverse consequences.
  • Failure to comply with data privacy and security laws, regulations and other obligations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, negative publicity, and/or other adverse consequences that could negatively affect our operating results and business.
  • The use of new and evolving technologies, such as AI, in our business may result in spending material resources and presents risks and challenges that can impact our business including by posing security and other risks to our confidential and/or proprietary information, including personal information, and as a result we may be exposed to reputational harm and liability.
  • Foreign data protection laws, including the European Union’s General Data Protection Regulation (the EU GDPR), and the UK equivalent of the same (the UK GDPR, together with the EU GDPR, the GDPR) may also apply to our processing of health-related and other personal data regardless of where the processing in question is carried out.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited.
  • Changes in tax law may adversely affect us or our investors.
  • We have incurred, and will continue to incur, significant increased costs as a result of operating as a public company, and our management is devoting substantial time and resources to compliance initiatives.
  • As a public company, we are obligated to maintain proper and effective internal controls over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our Series A common stock.
  • Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
  • Risks related to our Series A common stock
  • Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.
  • Our stock price has been and may continue to be volatile, and purchasers of our Series A common stock could incur substantial losses.
  • The dual series structure of our common stock may limit our Series A common stockholders’ ability to influence corporate matters and may limit visibility with respect to certain transactions.
  • Future sales and issuances of our Series A common stock, or rights to purchase our Series A common stock, could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  • We are an “emerging growth company” and a “smaller reporting company” and our election of reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our Series A common stock less attractive to investors
  • Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.
  • We may incur significant costs from class action litigation due to our expected stock volatility.
  • Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
  • Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
  • General risk factors
  • Our operations are vulnerable to interruption by earthquake, fire, power loss, telecommunications failure, terrorist activity and other events beyond our control, which could harm our business.
  • If securities or industry analysts issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
  • Unfavorable global political or economic conditions could adversely affect our business, financial condition or results of operations.

Legal proceedings

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which would have a material adverse effect on our results of operations, financial condition or cash flows.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62